title: Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.
abstract: Despite the strides that immunotherapy has made in mediating tumor regression, the clinical effects are often transient, and therefore more durable responses are still needed. The temporary nature of the therapy-induced immune response can be attributed to tumor immune evasion mechanisms, mainly the effect of suppressive immune cells and, in particular, regulatory T cells (Treg). Although the depletion of Tregs has been shown to be effective in enhancing immune responses, selective depletion of these suppressive cells without affecting other immune cells has not been very successful, and new agents are sought. We found that PI3K-Akt pathway inhibitors selectively inhibit Tregs with minimal effect on conventional T cells (Tconv). Our results clearly show selective in vitro inhibition of activation (as represented by a decrease in downstream signaling) and proliferation of Tregs in comparison with Tconvs when treated with different Akt and PI3K inhibitors. This effect has been observed in both human and murine CD4 T cells. In vivo treatment with these inhibitors resulted in a significant and selective reduction in Tregs in both naïve and tumor-bearing mice. Furthermore, these PI3K-Akt inhibitors led to a significant therapeutic antitumor effect, which was shown to be Treg dependent. Here, we report the use of PI3K-Akt pathway inhibitors as potent agents for the selective depletion of suppressive Tregs. We show that these inhibitors are able to enhance the antitumor immune response and are therefore promising clinical reagents for Treg depletion.
authors: Georgia Regents University Cancer Center, Augusta, Georgia.
authors: Rasha
authors: R
authors: Abu-Eid
authors: National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors: Raed N
authors: RN
authors: Samara
authors: National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors: Laurent
authors: L
authors: Ozbun
authors: National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors: Maher Y
authors: MY
authors: Abdalla
authors: National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
authors: Jay A
authors: JA
authors: Berzofsky
authors: bluebird bio, Cambridge, Massachusetts.
authors: Kevin M
authors: KM
authors: Friedman
authors: Georgia Regents University Cancer Center, Augusta, Georgia.
authors: Mikayel
authors: M
authors: Mkrtichyan
authors: Georgia Regents University Cancer Center, Augusta, Georgia. SKhleif@gru.edu.
authors: Samir N
authors: SN
authors: Khleif
mesh_terms: D000818:Animals; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology*; D051057:Proto-Oncogene Proteins c-akt / Q000276:immunology*; D015398:Signal Transduction / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt